CrossrefInfokarte
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
Clinical Colorectal Cancer · 2019-06 · 18 (2) · 125-132.e2
DOI: 10.1016/j.clcc.2019.02.004 ↗Abstract
Kein Abstract verfügbar.
EUVIMED